Literature DB >> 1446756

Ocular hypertension: correlation of anterior chamber angle width and risk of progression to glaucoma.

P K Wishart1, M Batterbury.   

Abstract

Twenty five patients with ocular hypertension (OH) and a narrow angle and 34 patients with OH and an open angle were followed for an average of six years. One eye of each patient had been randomly assigned to treatment with topical timolol. A shallow axial anterior chamber depth and a narrow angle (van Herick Grade 2 or less) was associated with the development of angle-closure glaucoma (ACG) in the narrow angle group, but the open angle group developed significantly more visual field loss. Nine patients (36%) in the narrow angle group developed ACG, and nine patients (26.5%) in the open angle group developed glaucomatous discs and field loss. The reduction in intraocular pressure due to topical timolol was equal in the narrow angle and the open angle groups, but topical timolol did not protect against the development of angle-closure glaucoma or visual field loss.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1446756     DOI: 10.1038/eye.1992.48

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  3 in total

1.  Comparison of techniques for measuring anterior chamber depth: Orbscan imaging, Smith's technique, and van Herick's method.

Authors:  Frank Eperjesi; Claire Holden
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-09-10       Impact factor: 3.117

Review 2.  Medical interventions for primary open angle glaucoma and ocular hypertension.

Authors:  C Vass; C Hirn; T Sycha; O Findl; P Bauer; L Schmetterer
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

3.  Progression of Primary Angle Closure Suspect to Primary Angle Closure and Associated Risk Factors: The Handan Eye Study.

Authors:  Ye Zhang; Ravi Thomas; Qing Zhang; Si Zhen Li; Ning Li Wang
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-06-01       Impact factor: 4.799

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.